Clinical Trial Update: Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating dapagliflozin for renal outcomes and bone mineral disorder in non-diabetic chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Chronic Kidney Disease-mineral and Bone Disorder

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• FARXIGA (dapagliflozin)

Snippet

Sponsor: Mansoura University | Conditions: Chronic Kidney Diseases, Bone Diseases, Metabolic | Phase 4 | Status: COMPLETED